Dr. Alexander Miller Joins InforMedix Scientific Advisory Board.ROCKVILLE, Md. -- InforMedix, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :IFMX IFMX Informix Corporation ) today announced that Alexander L. Miller, M.D. has joined the Company's Scientific Advisory Board. A prominent psychiatrist with extensive experience conducting pharmaceutical studies on schizophrenia and related disorders, including the use of patient-reported outcomes measures, Dr. Miller will advise InforMedix's management team on issues concerning the development and commercialization of its Med-eMonitor System(TM), a compliance-enhancing and monitoring platform that enables patients to report medication-compliance and electronic patient reported outcomes (ePRO) data to online databases via a hand-held electronic device. "Dr. Miller's extensive background in clinical research and psychiatry will enable InforMedix to obtain valuable feedback on the many medication-compliance challenges researchers face in clinical trials, and how the Med-eMonitor can address those issues," said Dennis H. Langer, M.D., J.D., chairman of InforMedix's Advisory Board. "Dr. Miller has used the Med-eMonitor System in his research activities and is aware of its strengths and capabilities," said Janet Campbell, president and COO of InforMedix. "Dr. Miller's experience in working closely with those in the pharmaceutical industry coupled with his knowledge in the use of the Med-eMonitor System offers InforMedix the perfect combination. He will be a strong addition to our Advisory Board." When asked what attracted Dr. Miller to InforMedix's Scientific Advisory Board he stated, "The group of people on the InforMedix Scientific Advisory Board is very impressive and innovative in the pharmaceutical industry. The Med-eMonitor product has tremendous potential for improving clinical trials as well as ordinary medical care." Dr. Miller received a B.A. from Yale University Yale University, at New Haven, Conn.; coeducational. Chartered as a collegiate school for men in 1701 largely as a result of the efforts of James Pierpont, it opened at Killingworth (now Clinton) in 1702, moved (1707) to Saybrook (now Old Saybrook), and in 1716 was and a M.D. from Washington University Washington University, at St. Louis, Mo.; coeducational; est. as Eliot Seminary 1853, opened 1854, renamed 1857. It has a well-known medical school and school of social work as well as research centers for radiology, space studies, engineering computing, and the Medical School in St. Louis, MO. He is a professor of psychiatry and director for the Division of Schizophrenia and Related Disorders at the University of Texas Health Science Center in San Antonio San Antonio (săn ăntō`nēō, əntōn`), city (1990 pop. 935,933), seat of Bexar co., S central Tex., at the source of the San Antonio River; inc. 1837. , TX. Additionally, Dr. Miller is the director of clinical research at San Antonio State Hospital. Dr. Miller has been awarded more than 30 grants to conduct studies related to mental health, and is currently using the Med-eMonitor in a study of schizophrenic patients. He has been published over 100 times in medical publications including the Journal of Neurochemistry neurochemistry /neu·ro·chem·is·try/ (-kem´is-tre) the branch of neurology dealing with the chemistry of the nervous system. neu·ro·chem·is·try n. , Biochemical Journal The Biochemical Journal (Biochem J or BJ) is a peer-reviewed academic journal which covers all aspects of biochemistry, as well as cell and molecular biology. It is published by Portland Press on behalf of the Biochemical Society from offices in London, UK. , American Journal of Psychiatry The American Journal of Psychiatry (AJP) is the most widely read psychiatric journal in the world. It covers topics on biological psychiatry, treatment innovations, forensic, ethical, economic, and social issues. and Journal of Neurochemistry. Additionally, Dr. Miller has served as a consultant to leading pharmaceutical companies including AstraZeneca, Eli Lilly Eli Lilly can refer to:
About InforMedix InforMedix has developed the Med-eMonitor System to provide real-time medical management and patient communications for clinical drug trials. The Company has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system In telecommunication, a communications system is a collection of individual communications networks, transmission systems, relay stations, tributary stations, and data terminal equipment (DTE) usually capable of interconnection and interoperation to form an integrated whole. to enable pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. , and medical researchers to efficiently monitor and manage patients' medication compliance, protocol adherence, clinical response, and safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in clinical drug trials. The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 14 patents pending. The Company's patents have been cited as prior art by patent examiners in over 150 other issued patents. Safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. References made to the discussion of the risk factors are detailed in the Company's filings with the Securities and Exchange Commission, including the report on Form 10-QSB for the quarter ended March 31, 2004, our Annual Report on Form 10-KSB for the year ended December 31, 2003, our prospectus dated May 28, 2004, and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion